ObsEva SA (OBSV)
|52 Week Range||0.13-2.14|
|1y Target Est||-|
|DCF Unlevered||OBSV DCF ->|
|DCF Levered||OBSV LDCF ->|
|Debt / Equity||-633.72%||Strong Sell|
Upgrades & Downgrades
Latest OBSV news
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
1 December 2022
ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Hot Penny Stocks For Your Buy List in September? 3 to Watch
30 August 2022
Here's what you need to know about trading penny stocks on August 30th The post Hot Penny Stocks For Your Buy List in September? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Info...
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
3 August 2022
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is ObsEva (OBSV) Stock Down 70% Today?
27 July 2022
Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning.
ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress
5 July 2022
Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fi...
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
17 June 2022
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
ObsEva SA (OBSV) CEO Brian O'Callaghan on Q1 2022 Results - Earnings Call Transcript
17 May 2022
ObsEva SA (NASDAQ:OBSV ) Q1 2022 Results Conference Call May 17, 2022 8:00 AM ET Company Participants Katja Buhrer - Chief Strategy Officer Brian O'Callaghan - Chief Executive Officer Brandi Howard - ...
7 Penny Stocks With 10x Potential This Year
17 May 2022
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
16 May 2022
GENEVA, Switzerland May 1 6 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Company Ma...